Company Overview and News
TOKYO, July 18 (Reuters) - Japan’s Nikkei share average advanced to a more than one-month high on Wednesday as exporters such as automakers and technology firms got a boost after the dollar hit a six-month high against the yen.
7261 9681 ADTTF MZDAY TM TYT TOYOF 2531 TTDKF TKHIY MZDAF 7203 ATEYY
Japan's Nikkei share average soared to a more than one-month high on Wednesday morning as exporters such as automakers and technology firms got a boost after the dollar hit a six-month high against the yen.
7261 PCRFY 9681 ADTTF MZDAY TM TYT TOYOF 2531 TTDKF TKHIY MZDAF 7203 ATEYY
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JBK 9681 GS.PRICL GSC TFG GS.PRB DSECF GS.PRA GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC 8601 DSEEY GJS GS.PRN GS.PRK
The New York Yankees and Boston Red Sox will clash in the first Major League Baseball games in Europe next year as the sport looks to grow its global fanbase, MLB chiefs announced on Tuesday.
* TOKYO DOME CORP’S OPERATING PROFIT LOOKS TO HAVE FALLEN 10 PERCENT TO A LITTLE OVER 11 BILLION YEN FOR THE YEAR ENDED IN JANUARY - NIKKEI
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...